News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
683,370 Results
Type
Article (38975)
Company Profile (277)
Press Release (644118)
Section
Business (203824)
Career Advice (1985)
Deals (35357)
Drug Delivery (84)
Drug Development (80777)
Employer Resources (168)
FDA (16085)
Job Trends (14797)
News (344471)
Policy (32429)
Tag
Academia (2530)
Alliances (49035)
Alzheimer's disease (1215)
Approvals (16004)
Artificial intelligence (116)
Bankruptcy (352)
Best Places to Work (11465)
Biotechnology (196)
Breast cancer (108)
Cancer (906)
Cardiovascular disease (81)
Career advice (1656)
Cell therapy (200)
Clinical research (63931)
Collaboration (326)
Compensation (168)
COVID-19 (2524)
Cystic fibrosis (78)
Data (862)
Diabetes (134)
Diagnostics (6097)
Earnings (84172)
Employer resources (146)
Events (108898)
Executive appointments (248)
FDA (16530)
Funding (291)
Gene therapy (149)
GLP-1 (560)
Government (4318)
Healthcare (18654)
Infectious disease (2599)
Inflammatory bowel disease (102)
Interviews (308)
IPO (16271)
Job creations (3622)
Job search strategy (1415)
Layoffs (408)
Legal (7848)
Lung cancer (155)
Manufacturing (152)
Medical device (13147)
Medtech (13152)
Mergers & acquisitions (19108)
Metabolic disorders (365)
Neuroscience (1456)
NextGen Class of 2024 (6496)
Non-profit (4462)
Northern California (1212)
Obesity (217)
Opinion (176)
Patents (94)
People (56128)
Phase I (19830)
Phase II (28150)
Phase III (21016)
Pipeline (212)
Postmarket research (2553)
Preclinical (8431)
Radiopharmaceuticals (234)
Rare diseases (180)
Real estate (5888)
Regulatory (21441)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1085)
Startups (3560)
United States (11710)
Vaccines (539)
Weight loss (161)
Date
Today (288)
Last 7 days (845)
Last 30 days (2972)
Last 365 days (35694)
2024 (30472)
2023 (40075)
2022 (51173)
2021 (55715)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (187)
Asia (37014)
Australia (6037)
California (2741)
Canada (1180)
China (209)
Colorado (119)
Connecticut (123)
Europe (79244)
Florida (396)
Georgia (100)
Illinois (308)
Indiana (179)
Kansas (95)
Maryland (516)
Massachusetts (2248)
Michigan (144)
Minnesota (250)
New Jersey (829)
New York (842)
North Carolina (665)
Northern California (1212)
Ohio (127)
Pennsylvania (748)
South America (1091)
Southern California (1085)
Texas (385)
Utah (80)
Washington State (323)
683,370 Results for "altimmune inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioCapital
Altimmune to Participate at Two Upcoming Conferences
Altimmune, Inc. today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on behalf of the Company at the following two upcoming conferences.
May 1, 2024
·
1 min read
Business
Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that Richard Eisenstadt, the Company’s Chief Financial Officer, passed away unexpectedly on Monday, June 24, 2024.
June 26, 2024
·
1 min read
BioCapital
Altimmune to Participate at Two Upcoming Investor Conferences - May 29, 2024
Altimmune, Inc. today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences.
May 29, 2024
·
1 min read
Drug Development
Altimmune Targets Obesity Market With Weight-Loss Drug That Preserves Lean Muscle Mass
Altimmune’s obesity candidate pemvidutide strongly preserved lean muscle mass, with fat accounting for more than 78% of weight lost by participants in a Phase II study.
June 24, 2024
·
2 min read
·
Tristan Manalac
BioCapital
Altimmune to Participate at Two Upcoming May 2024 Investor Conferences
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:
May 7, 2024
·
1 min read
Business
Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced financial results for the first quarter ended March 31, 2024, and provided a business update.
May 9, 2024
·
9 min read
BioCapital
Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024
Altimmune, Inc. today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) will be presented at the EASL International Liver Congress™ 2024 in Milan, Italy.
May 29, 2024
·
3 min read
BioCapital
Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways
Altimmune, Inc. today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 2nd Annual Virtual Obesity Investor Day, being held on June 26, 2024, to discuss key takeaways from the American Diabetes Association’s (ADA) Scientific Sessions.
June 20, 2024
·
1 min read
BioCapital
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions
Altimmune, Inc. today announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH, at the American Diabetes Association’s (ADA) 84th Scientific Sessions, to be held in Orlando, FL from June 21-24, 2024.
June 18, 2024
·
2 min read
Press Releases
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
November 5, 2024
·
1 min read
1 of 68,337
Next
